Compare ZTO & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | DVA |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 14.9B |
| IPO Year | 2016 | 2003 |
| Metric | ZTO | DVA |
|---|---|---|
| Price | $20.95 | $183.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | $23.65 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.7M | 670.7K |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.86 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $14.01 | $3.85 |
| Revenue Next Year | $9.12 | $3.07 |
| P/E Ratio | ★ $21.83 | $26.43 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $18.11 | $101.00 |
| 52 Week High | $26.20 | $247.49 |
| Indicator | ZTO | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 28.52 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $22.84 | N/A |
| Average True Range (ATR) | 0.38 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 18.07 | 0.00 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 20.1% in 2026. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and a major shareholder with 78.7% voting rights as of March 31, 2026. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around a 9.3% interest.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.